© 2020 MJH Life Sciences and Neurology Live. All rights reserved.
© 2020 MJH Life Sciences™ and Neurology Live. All rights reserved.
September 21, 2020
Atara Biotherapeutics’ allogeneic EBV-targeted T-cell therapy, ATA188, is well-tolerated in phase 1, with a dose identified for the randomized placebo-controlled portion of the study.
Future research may help better characterize whether fatigue interventions aimed at one patient population may be effective in the other.
In honor of World Alzheimer’s Day, NeurologyLive is sharing some of the latest clinical developments and thoughts from leaders in the field.
Experts review the challenges of managing OFF episodes in Parkinson's disease and the current treatment options to optimize therapy.
David Dodick, MD, reviews changes to the treatment landscape for acute migraine.
The neurologist at Mayo Clinic shared his thoughts on the need to raise awareness of Alzheimer disease on World Alzheimer’s Day.
September 20, 2020
Marinus Pharmaceuticals’ positive allosteric GABAA receptor modulator ganaxolone was associated with significant median reductions in 28-day major motor seizure frequency compared to placebo.
September 19, 2020
A pair of datasets from the phase 3b CASTING study of ocrelizumab (Ocrevus; Genentech) suggest that patients treated with the agent experienced high rates of no evidence of disease activity status regardless of prior DMT exposure.
Neurology News Network for the week ending September 19, 2020.
September 18, 2020
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 18, 2020.